Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MR-130A-01 is a progestin-only transdermal contraceptive patch containing norelgestromin (NGMN) as its active ingredient. It is being developed by Viatris (formerly Mylan Pharmaceuticals) as a female contraceptive option. The patch works through a progesterone receptor agonist mechanism, which helps prevent pregnancy by inhibiting ovulation and affecting other physiological functions related to the reproductive system[1][5]. Norelgestromin is already available in combination with ethinyl estradiol (EE) in combined hormonal contraceptive transdermal systems such as Xulane (US) and Evra (EU), but MR-130A-01 is a progestin-only formulation[6][9]. The patch is designed to be applied to the skin (upper outer arm, abdomen, buttock, or back) and changed weekly[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MR-130A-01.